

UNITED STAT DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	AT	TORNEY DOCKET NO.	
09/506,5	78 02/18.	/00 SPERTINI	; -	18519-001	
-		HM12/0405	EX	EXAMINER	
Mintz Levin Cohn Ferris One Financial Center Boston MA 02111		erris Glovsky and Pope er	HLIYNH ART UNIT	PAPER NUMBER	
And the first for the first 1 1 1 1	r (2111		1644 DATE MAILED:	7	
			DAIL MAILED.	04/05/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

		Application No.	Applicant(s)			
	Office Action Summary	09/506,978	SPERTINI, FRANCOIS			
	Office Action Summary	Examiner	Art Unit			
		"Neon" Phuong Huynh	1644			
 Period fo	The MAILING DATE of this communication apper	ears on the cover sheet with the co	prrespondence address			
THE N - Exten after S - If the - If NO - Failur - Any re	DRTENED STATUTORY PERIOD FOR REPL'MAILING DATE OF THIS COMMUNICATION. sions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a repl period for reply is specified above, the maximum statutory period e to reply within the set or extended period for reply will, by statute the ply received by the Office later than three months after the mailing dipatent term adjustment. See 37 CFR 1.704(b).	136 (a). In no event, however, may a reply be till by within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	mely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
1) 🗌	Responsive to communication(s) filed on	·				
2a) <u></u>	This action is FINAL . 2b) The	nis action is non-final.				
3)	Since this application is in condition for allow closed in accordance with the practice under	ance except for formal matters, p Ex parte Quayle, 1935 C.D. 11,	rosecution as to the merits is 453 O.G. 213.			
Dispositi	on of Claims					
4) 🖾	Claim(s) 1-35 is/are pending in the application	n.				
	4a) Of the above claim(s) is/are withdra	wn from consideration.				
5)	Claim(s) is/are allowed.					
6)	Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8)⊠	Claims <u>1-35</u> are subject to restriction and/or	election requirement.				
Applicati	on Papers					
	The specification is objected to by the Examir	ner.				
1 1 1 1 <u>1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 </u>		to by the Examiner.				
•	The proposed drawing correction filed on	is: a) approved b) disap	proved.			
	The oath or declaration is objected to by the E					
Priority I	ınder 35 U.S.C. § 119					
-	Acknowledgment is made of a claim for foreig	un priority under 35 U.S.C. δ 1190	a)-(d) or (f).			
	Ackinowledgment is made of a claim for foreign All b) Some * c) None of:	in priority under oo o.o.o. § 110(a) (a) 51 (i):			
a)		ats have been received				
			tion No			
	2. Certified copies of the priority document3. Copies of the certified copies of the priority					
* (application from the International B See the attached detailed Office action for a lis	ureau (PCT Rule 17.2(a)).				
14)	Acknowledgement is made of a claim for dom	nestic priority under 35 U.S.C. § 1	19(e).			
Attachmon	t(e)					
Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s)						
16) 🔲 Not	ice of References Cited (P10-692) ice of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449) Paper No(s	19) Notice of Inform	al Patent Application (PTO-152)			




Art Unit: 1644

DETAILED ACTION

- 1. Please note the location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1644, Group 1640, Technology Center 1600.
- 2. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. 1.821(a)(1) and (a)(2). It is noted, however, that this application fails to comply with the sequence rules which require a submission for all sequences of more than 9 nucleotides or 3 amino acids (see 37 C.F.R. 1.821-1.825). Please see enclosed notice to comply.
- 3. Claims 1-35 are pending in the instant application.

Election/Restrictions

- 4. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-3, 7-11, 18-26, 27 and 35, drawn to a polypeptide consisting of SEQ ID NO: 1, classified in 530, subclass 350.
 - II. Claims 4, 7-11, 18-26, 27 and 35, drawn to a polypeptide consisting of SEQ ID NO: 2, classified in 530, subclass 350.
 - III. Claims 5, 7-11, 18-26, 27 and 35, drawn to a polypeptide consisting of SEQ ID NO: 3, classified in 530, subclass 350.
 - IV. Claims 6, 7-11, 18-26, 27 and 35, drawn to a polypeptide consisting of SEQ ID NO: 4, classified in 530, subclass 350.
 - V. Claims 12-17, and 35 drawn to a monoclonal antibody that binds to polypeptide consisting of SEO ID NO: 1, classified in 530, subclass 387.1.
 - VI. Claims 28-30, drawn to a method of modulating immune response, classified in Class 424, subclass 184.1.
 - VII. Claims 31-33, drawn to a method of identifying an individual at risk of bee venom hypersensitivity, classified in Class 435, subclass 7.1.
 - VIII. Claims 34, drawn to a method of purifying the polypeptide, classified in Class 530, subclass 412.



Art Unit: 1644

The inventions of Groups I-VIII are distinct, each from the other because of the following reasons:

Inventions of I-V are different and distinct product. Polypeptides and antibodies differ with respect to their structures and biochemical properties, a person of ordinary skill in the art would not envision one in view of the other. In addition, they differ in mode of action. Therefore, they are patently distinct.


Inventions of VI-VIII are different methods, which require different ingredient, process steps and end point. Therefore, they are patently distinct.

Inventions of (I-V) and VI-VIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)).

In the instant case, the polypeptide can be used as an immunogen to make antibody as well as therapeutic methods claimed. Therefore, they are patentably distinct.

Because these inventions are distinct for the reasons given above and the searches are not co-extensive, restriction for examination purposes as indicated is proper.

- 5. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phuong Huynh "NEON" whose telephone number is (703) 308-4844. The examiner can normally be reached Monday through Friday from 9:00 am to 5:30 p.m. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.



Art Unit: 1644

7. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform to the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Phuong N. Huynh, Ph.D.

Patent Examiner

Technology Center 1600

April 5, 2001

Patrick J. Nolan, Ph.D.

Primary Examiner

Technology Center 1600

Application : 09/506,978 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

_		
Ø	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
d		This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
J	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6	. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7	. Other:
Αp	p	licant Must Provide:
·	, μ	An <u>initial or substitute computer readable form (CRF) copy of the "Sequence Listing".</u>
Ø	/ # il	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
d	8	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or .825(b) or 1.825(d).
Fc	or ·	questions regarding compliance to these requirements, please contact:
Fo	or	Rules Interpretation, call (703) 308-4216
Fo	r	CRF Submission Help, call (703) 308-4212
Pa	ate	entIn Software Program Support (SIRA) Technical Assistance703-287-0200
		To Purchase Patentin Software703-306-2600